TITLE

Ghost Management: How Much of the Medical Literature Is Shaped Behind the Scenes by the Pharmaceutical Industry?

AUTHOR(S)
Sismondo, Sergio
PUB. DATE
September 2007
SOURCE
PLoS Medicine;Sep2007, Vol. 4 Issue 9, pe286
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Sismondo discusses how pharmaceutical companies and their agents shape multiple steps in the research, analysis, writing, and publication of articles.
ACCESSION #
27004429

 

Related Articles

  • Biomedical Industrial Sponsorship and Its Impact on the Medical Literature. Morris, Peter J. // World Journal of Surgery;Aug2006, Vol. 30 Issue 8, p1371 

    The article focuses on the issue of the influence of biomedical industrial sponsorship on medical literature. In order to bring a new drug onto the market clinical trials are conducted. These trials take place in clinics in both university and nonuniversity institutions and, for the most part,...

  • Drug giants fail to name compounds in trial database. Wadman, Meredith // Nature;6/2/2005, Vol. 435 Issue 7042, p548 

    The article reports that an international group of medical editors is challenging several leading pharmaceutical companies, saying that their reporting of clinical trials is deliberately incomplete. They argue that leading pharmaceutical companies are obeying the letter but not the spirit of a...

  • Forcing Pharma's Hand. Varmazis, Catherine // Bio-IT World;Jul/Aug2007, Vol. 6 Issue 6, p38 

    The article focuses on the issues concerning the policies issued by the International Committee of Medical Journal Editors (ICMJE). The policies were issued following criticisms on the hesitance of pharmaceutical companies to register ongoing clinical trials. According to ICMJE, the update on...

  • Ghosts still present in the medical machine. Jones, Nicola // Nature;9/17/2009, Vol. 461 Issue 7262, p325 

    The article reports that ghostwriting in medical literature remains, despite the policy changes in drug-company and efforts of journals to cut down the practice in the U.S. It states that the ghostwriting, is a practice that involves pharmaceutical companies designing and paying for studies or...

  • Quality of claims, references and the presentation of risk results in medical journal advertising: a comparative study in Australia, Malaysia and the United States. Othman, Noordin; Vitry, Agnes I.; Roughead, Elizabeth E. // BMC Public Health;2010, Vol. 10 Issue 1, p294 

    Background: Journal advertising is used by pharmaceutical companies to disseminate medicine information to doctors. The quality of claims, references and the presentation of risk results in Australia and the US has been questioned in several studies. No recent evidence is available on the...

  • orphan.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1646 

    Definitions of various terms are presented including "orphan," referring to a minor with deceased or unknown parents, "orphan (o.) disease," pertaining to a rare disease that lacks attention from medical researchers or pharmaceutical firms and "o.drug," referring to drugs that are both effective...

  • Taking flight. Rhea, Shawn // Modern Healthcare;6/30/2008, Vol. 38 Issue 26, p32 

    The article discusses the results of a study titled "The Globalization of Innovation: Pharmaceuticals: Can India and China Cure the Global Pharmaceutical Market?" conducted by the Ewing Marion Kauffman Foundation. The study found that major pharmaceutical companies are making significant...

  • Drug firm research has lower impact.  // GP: General Practitioner;10/3/2012, p16 

    The article reports on the study which suggests that doctors are less likely to act on the findings of research funded by pharmaceutical companies in the U.S. It indicates that doctors were 37% less likely to consider prescribing a drug on the basis of studies from pharmaceutical companies. The...

  • Medicine and the future of health: reflecting on the past to forge ahead. Fisher, Dale; Wicks, Paul; Babar, Zaheer-Ud-Din // Journal of Pharmaceutical Policy & Practice;10/25/2016, Vol. 9, p1 

    The development of new therapies has a rich history, evolves quickly with societal trends, and will have an exciting future. The last century has seen an exponential increase in complex interactions between medical practitioners, pharmaceutical companies, governments and patients. We believe...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics